Toralizumab

Toralizumab was a humanized monoclonal antibody and an immunosuppressive drug. Possible indications included treatment of antibody-mediated disorders, T-cell-mediated diseases.
In Phase II clinical trials regarding multiple sclerosis and Crohn's disease, thromboembolisms occurred in at least three patients. A causal connection could not be proven, but since the same adverse effects were seen in trials with a similar antibody, the trials were halted.
The drug was developed by IDEC Pharmaceuticals Corporation.